Predict your next investment

HEALTHCARE | Drug Development
aerami.com

See what CB Insights has to offer

Founded Year

2010

Stage

Acq - Pending | Acquired

Total Raised

$115.12M

Valuation

$0000 

About Aerami Therapeutics

Aerami Therapeutics develops improved therapies for the treatment of severe respiratory and chronic diseases. Its lead asset is inhaled imatinib (AER-901) for the treatment of pulmonary arterial hypertension.

Aerami Therapeutics Headquarter Location

2520 Meridian Parkway Suite 400

Durham, North Carolina, 27713,

United States

415-769-4200

Latest Aerami Therapeutics News

Aerami Therapeutics, eager to breeze into smart inhaler market, unveils $250M SPAC deal

Dec 14, 2021

Dec 14, 2021 3:40pm Aerami Therapeutics will use the spoils from the deal to propel its lead candidate—a phase 1 drug-device combo—into a planned phase 2/3 trial in 2022. (Getty Images) Biopharma is no stranger to the special purpose acquisition company dealmaking spree of 2020 and 2021. Now, inhaled therapy specialist Aerami Therapeutics is getting in on the action, just in time to ride the SPAC train into the new year. Clinical-stage inhaled drug delivery developer Aerami is joining forces with SPAC FoxWayne Enterprises Acquisition in a bid to go public, the companies said . The deal, which is expected to close in the first quarter of 2022, will see the combined company retain Aerami's current moniker, Aerami Therapeutics Holdings, with the biopharma's CEO, Steve Thornton, at the helm. Thornton will be joined by the rest of Aerami's current management team, the companies said in a release. The combined firm's common stock is expected to remain listed on the Nasdaq. With their forces combined, Aerami and FoxWayne expect to have a war chest of $58 million in cash proceeds currently in trust at FoxWayne, plus Aerami's existing cash resources at closing. Aerami will use the spoils from the deal to propel its lead candidate, AER-901—a combination drug-device prospect in phase 1 testing for pulmonary arterial hypertension (PAH)—into a planned phase 2/3 trial in 2022. The company thinks its drug, which is an inhaled, nebulized formulation of imatinib, could prove to be a disease-modifying therapy in PAH. Aerami estimates the PAH market is worth some $5 billion.

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Aerami Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Aerami Therapeutics is included in 1 Expert Collection, including Biopharma Tech.

B

Biopharma Tech

15,533 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Aerami Therapeutics Patents

Aerami Therapeutics has filed 25 patents.

The 3 most popular patent topics include:

  • Dosage forms
  • Drug delivery devices
  • Routes of administration
patents chart

Application Date

Grant Date

Title

Related Topics

Status

10/23/2018

8/24/2021

Diabetes, Protein domains, Insulin therapies, Autosomal recessive disorders, Food additives

Grant

Application Date

10/23/2018

Grant Date

8/24/2021

Title

Related Topics

Diabetes, Protein domains, Insulin therapies, Autosomal recessive disorders, Food additives

Status

Grant

Aerami Therapeutics Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Aerami Therapeutics Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.